Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Benzinga · 2d ago
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.